On June 18, Hims & Hers Health rose 5.04% in regular trading, trading at $32.87/share, with turnover of $486 million. The stock extended its recent strong rebound as multiple bullish catalysts continued to ferment.

On the news front, Goldman Sachs recently raised its global obesity drug market forecast for 2030 from $101 billion to $114 billion, a 13% increase, driven by rapid penetration of oral GLP-1 formulations. The bank noted oral drugs now account for 40%-50% of new prescriptions and are projected to contribute approximately $46 billion in revenue by 2030. Goldman Sachs also lowered its U.S. direct-sales channel price assumption by 20%, which could unlock roughly 17 million new potential patients in the U.S. alone.

Meanwhile, Hims & Hers Health's tracked sales data showed positive year-over-year growth in three of the most recent four weeks, signaling clear marginal improvement in business fundamentals and sustaining bullish sentiment. The company, a multi-specialty telehealth platform offering services in mental health, sexual health, dermatology, and primary care, reported a Q1 EPS loss of -$0.40 with revenue of $608 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)